And here we go with the return of soft bashing. The ovarian cancer trial did not "stop abruptly," it concluded and the company said that it was putting its funds toward the clinical trials that could be concluded quickly and relatively cheaply. Had the company decided to spend the next 5 years focusing on a cancer trial, instead of bringing some Brilacidin formulations and Prurisol to clinical trials, THEN people would have something to complain about.

But claiming that a clinical trial "abruptly stopped" implies that there was something wrong with the drug. There was NOT. There was just a shortage of money to run a lengthy, expensive trial that would have results only a long time in the future.

Perfect example of soft bashing: "I'm a bull but boy is this a red flag..."

"They" must be getting really worried, to resort to this level of BS aimed at a crowd of knowledgeable investors, who call BS when they see it.